The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...

Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

The CHMP positive opinions for the approval and the Type II extension of the indication are supported by data from the Phase III MARIPOSA study which evaluated Rybrevant in combination with Lazcluze ...

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

The CHMP's positive opinion, announced today, is based on results from the LAURA Phase III trial, which demonstrated that Tagrisso significantly extended median progression-free survival to over ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN) has received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for its drug ...

AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer ...